P-1251. Pharmacometric Analyses to Support Dose Selection of Zoliflodacin, a First-in-Class Oral Antibiotic Being Developed for the Treatment of Uncomplicated Gonorrhea
Sujata M. Bhavnani(Institute for Clinical Pharmacodynamics (United States)), Christopher M. Rubino(Institute for Clinical Pharmacodynamics (United States)), John P. O’Donnell(Entasis Therapeutics (United States)), Alison Luckey(Global Antibiotic Research & Development Partnership), Pierre Daram(Global Antibiotic Research & Development Partnership), Anthony P Cammarata(Institute for Clinical Pharmacodynamics (United States)), Jeffrey Hammel(Mayo Clinic), Kajal Larson(Entasis Therapeutics (United States))
Cited by 4
Related Papers
The Impact of Morbid Obesity, Pneumoperitoneum, and Posture on Respiratory System Mechanics and Oxygenation During Laparoscopy
|Anesthesia & Analgesia|2002|198
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
|Journal of Antimicrobial Chemotherapy|2019|123
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
|The Lancet Infectious Diseases|2024|98
The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus <i>Acinetobacter baumannii-calcoaceticus</i> Complex
|Clinical Infectious Diseases|2023|32
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation
|European Journal of Clinical Pharmacology|2024|28